Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 11/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | ARG1 | P05089 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5789143 | 0.81 | DPP4 (0.39) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL5790339 | 0.81 | DPP8 (0.40) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL5790110 | 0.80 | AGTR2 (0.45) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL5790640 | 0.80 | DPP4 (0.40) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL5789948 | 0.75 | ALOX15 (0.40) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL5803469 | 0.74 | DPP8 (0.49) | DPP4DPP8DPP7 | |
| SCHEMBL5789987 | 0.74 | ACE (0.49) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL5787459 | 0.74 | ALOX15 (0.39) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL5790900 | 0.69 | DPP8 (0.41) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL27431628 | 0.68 | ACE (0.58) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622870-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | Prosidion Ltd. (GB) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004099134-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | PROSIDION LTD. (GB) | 2004-11-18 | — | — | WO | disclosed |
| US-20040229848-A1 | Glutaminyl based DP IV-inhibitors | PROSIDION LIMITED (GB) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229848-A1 | Glutaminyl based DP IV-inhibitors | DPP4, DPP3, DNPEP | ALOX15 4131/4885BLM 3796/4885PMP22 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.